[Research Report] The human vaccine adjuvants market value is projected to grow from US$ 1,571.41 million in 2022 to US$ 4,489.23 million by 2030. The human vaccine adjuvants market is further anticipated to record a CAGR of 14.0% from 2022 to 2030.
Market Insights and Analyst View:
Adjuvants are important components in vaccine formulation as they help strengthen the body's immune response to antigens, ultimately contributing to vaccine effectiveness. Adjuvants can range from simple synthesized small molecule compounds to complicated natural extracts and particulates. Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and the growing focus on immunization programs. However, the manufacturing complexities and regulatory challenges hinder the market growth.
Growth Drivers and Restraints:
The rising prevalence of chronic diseases is fueling the demand for vaccine adjuvants. Adjuvants are added to vaccines to enhance the efficacy and body's immune response. They help improve the effectiveness of vaccines by stimulating a stronger and longer-lasting immune response. As the demand for vaccines to prevent and manage chronic diseases continues to grow, the demand for adjuvants also increases. Chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory diseases are rising globally. According to the World Health Organization, the most noncommunicable disease-related deaths occur due to cardiovascular diseases, accounting for ∼17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ∼24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions.
The rising geriatric population is also bolstering the demand for vaccines. As per a study published in January 2023 by NCBI, in the US, the number of people aged 50 years and older will reach 221.13 million by 2050, a rapid increase from 137.25 million in 2020. People aged 50 and above are expected to suffer from at least one chronic disease, and the figure is projected to rise by 99.5% from 71.52 million in 2020 to 142.66 million by 2050. Also, it is projected that ~14 million people are likely to suffer from multimorbidity by 2050.
The prevalence of hepatitis is also increasing. Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030 through vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the human vaccine adjuvants market.
However, manufacturing human vaccine adjuvant is a complex process involving stringent regulatory requirements and quality control measures. The production of adjuvants requires specialized equipment and facilities with strict adherence to Good Manufacturing Practices (GMP) and other regulatory standards to ensure the final product's purity, safety, and efficacy. This can pose significant challenges for manufacturers, especially smaller companies or new entrants, owing to limited resources and expertise to meet these requirements.
Trends:
Precision or personalized vaccines are a growing trend in the human vaccine adjuvants market. These vaccines target specific genetic or molecular characteristics of a patient's disease, assisting the production of vaccines tailored to each patient's unique immune response. The technique can potentially improve vaccination efficacy and safety, leading to increased interest in personalized vaccines for treating diseases such as cancer, infectious diseases, and autoimmune disorders.
Adjuvants that can boost the immune response to these tailored vaccines are required to produce personalized vaccines. Adjuvants are essential in stimulating the immune system to develop a targeted and powerful response to the vaccine's specific antigens. As a result, there is an increasing demand for adjuvants that can effectively boost immune responses to personalized vaccines. In recent years, there has been a strong emphasis on R&D efforts to identify and create adjuvants that can increase the immune response to personalized vaccines. For instance, in December 2022, Moderna and Merck announced mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA(R) (pembrolizumab). Adjuvant treatment with mRNA-4157/V940 in combination with KEYTRUDA reduced the risk of recurrence or death by 44% compared with KEYTRUDA alone.
Regulatory bodies and healthcare organizations recognize personalized vaccines' potential for enhancing public health outcomes. For instance, in January 2023, BioNTech and the UK government signed a wide-reaching Memorandum of Understanding (MoU) to provide up to 10,000 patients with personalized mRNA cancer immunotherapies by 2030. This has increased funding for research and development initiatives in this field and measures to expedite regulatory routes for personalized vaccines and adjuvants. Thus, adjuvants that effectively improve the immune response to personalized vaccinations are increasingly being developed, enhancing vaccine efficacy and safety. This trend drives substantial innovation and investment in the human vaccine adjuvants market.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Human Vaccine Adjuvants Market: Strategic Insights
Market Size Value in US$ 1,571.41 million in 2022 Market Size Value by US$ 4,489.23 million by 2030 Growth rate CAGR of 14.0% from 2022 to 2030 Forecast Period 2022-2030 Base Year 2022
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Human Vaccine Adjuvants Market: Strategic Insights
| Market Size Value in | US$ 1,571.41 million in 2022 |
| Market Size Value by | US$ 4,489.23 million by 2030 |
| Growth rate | CAGR of 14.0% from 2022 to 2030 |
| Forecast Period | 2022-2030 |
| Base Year | 2022 |
Akshay
Have a question?
Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Report Segmentation and Scope:
The global human vaccine adjuvants market is segmented on the basis of type, application, and end user. Based on type, the market is divided into particulate adjuvants, emulsion adjuvants, combination adjuvants, and others. The human vaccine adjuvants market, by application, is divided into influenza, hepatitis, human papilloma virus (HPV), and others. In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. Geographically, the human vaccine adjuvants market is segmented into North America (the US, Canada, and Mexico), Europe (Germany, France, Italy, the UK, Russia, and the Rest of Europe), Asia Pacific (Australia, China, Japan, India, South Korea, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
Segmental Analysis:
Based on type, the human vaccine adjuvants market is segmented into particulate adjuvants, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register a higher CAGR in the market from 2022 to 2030. Particulate adjuvants consist of particles, often of nanometer or micrometer size, designed to mimic pathogens or cellular structures, stimulating a robust immune response. These adjuvants enhance antigen uptake by immune cells and promote immune activation. Notable examples of particulate adjuvants include aluminum salts (Alum), which have been used for decades in human vaccines to enhance antibody responses, and newer developments such as virus-like particles (VLPs) and nanoparticle-based adjuvants.
Human Vaccine Adjuvants Market, by Type – 2022 and 2030
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Influenza vaccines are crucial for preventing seasonal flu outbreaks and potential pandemics. They target a rapidly evolving virus, requiring continual vaccine updating to match circulating strains. Adjuvants used in influenza vaccines enhance immune responses, particularly in high-risk populations such as the elderly or immunocompromised individuals. They also support the development of broadly protective, cross-reactive immune responses.
In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030. Pharmaceutical and biotechnology companies play a central role in the research, development, and commercialization of vaccines, including adjuvanted vaccine formulations, targeting diverse infectious diseases and health conditions. These companies are at the forefront of vaccine innovation, driving the discovery and optimization of adjuvant technologies, vaccine candidates, and adjuvanted vaccine formulations through preclinical and clinical development stages.
Regional Analysis:
Geographically, the human vaccine adjuvants market is segmented into North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2022, North America held the largest share of the global human vaccine adjuvants market. Asia Pacific is estimated to register the highest CAGR during 2022–2030.
The US holds a significant share of the human vaccine adjuvants market in North America. The market growth in this country is mainly ascribed to rising government spending on healthcare and a surging demand for novel vaccine formulations to treat infectious diseases more efficiently. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019–2028, reaching US$ 6.2 trillion by 2028. The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants.
According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US. According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea. Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the human vaccine adjuvants market growth in the US.
The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country. The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the human vaccine adjuvants market in the US.
Industry Developments and Future Opportunities:
Various initiatives by key players operating in the global human vaccine adjuvants market are listed below:
- In December 2023, Health Canada approved a supplement to a New Drug Submission for Novavax Inc's Nuvaxovid as a primary series of two doses for adolescents aged 12 to 17 years.
- In November 2023, Seppic launched MONTANIDE GEL P PR, an aqueous adjuvant based on a polymeric technology exclusively dedicated to avian injectable vaccines, meeting the need for innocuity in the avian market. In addition, MONTANIDE GEL P PR is particularly stable and can resist destabilizing antigenic media frequently used in avian vaccines.
- In October 2023, SPI Pharma Inc. and Q-Vant Biosciences Inc. announced a partnership that combines Q-Vant's leadership in sustainable saponin extraction technology with SPI's global reach and servicing expertise in the pharmaceutical industry. The arrangement includes investment in the expansion of Q-Vant's proprietary 100% sustainable Q-SAP technology and an exclusive commercial agreement to accelerate the global adoption of their saponin adjuvants for veterinary and human vaccine formulations.
- In January 2023, Novavax Inc. partner SK Bioscience received expanded manufacturing and marketing approval from the Korean Ministry of Food and Drug Safety ("KMFDS") for Nuvaxovid for use as a booster in adults aged 18 and older.
Competitive Landscape and Key Companies:
Novartis AG, Dynavax Technologies Corp, CSL Ltd, Seppic SA, SPI Pharma Inc, Hawaii Biotech Inc, Croda International Plc, Novavax Inc, Phibro Animal Health Corp, and Creative Biolabs Inc are among the prominent players operating in the human vaccine adjuvants market. These companies focus on new technologies, advancements in existing products, and geographic expansions to meet the growing consumer demand worldwide and increase their product range in specialty portfolios.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Type, Application, End User, and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Adjuvants are important components in vaccine formulation as they help strengthen the body's immune response to antigens, ultimately contributing to vaccine effectiveness. Adjuvants can range from simple synthesized small molecule compounds to complicated natural extracts and particulates.
Key factors driving the human vaccine adjuvants market growth include the rising prevalence of chronic diseases and growing focus on immunization programs.
The human vaccine adjuvants market majorly consists of the players, including Novartis AG, Dynavax Technologies Corp, CSL Ltd, Seppic SA, SPI Pharma Inc, Hawaii Biotech Inc, Croda International Plc, Novavax Inc, Phibro Animal Health Corp, and Creative Biolabs Inc.
The human vaccine adjuvants market was valued at US$ 1,571.41 million in 2022.
The human vaccine adjuvants market is expected to be valued at US$ 4,489.23 million in 2030.
In terms of end user, the human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030.
Based on type, the human vaccine adjuvants market is segmented into particulate adjuvant, emulsion adjuvants, combination adjuvants, and others. The particulate adjuvant segment held a larger share of the market in 2022. However, the emulsion adjuvants segment is expected to register a higher CAGR in the market from 2022 to 2030.
By application, the human vaccine adjuvants market is segmented into influenza, hepatitis, human papillomavirus (HPV), and others. The influenza segment held the largest share of the market in 2022 and is expected to register the highest CAGR in the market from 2022 to 2030.
1. Introduction
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Human Vaccine Adjuvants Market Landscape
4.1 Overview
4.2 PEST Analysis
5. Human Vaccine Adjuvants Market – Key Market Dynamics
5.1 Human Vaccine Adjuvants Market – Key Market Dynamics
5.2 Market Drivers
5.2.1 Rising Prevalence of Chronic Diseases
5.2.2 Growing Focus on Immunization Programs
5.3 Market Restraints
5.3.1 Manufacturing Complexities and Regulatory Challenges
5.4 Market Opportunities
5.4.1 Growing Pharmaceutical Industry
5.5 Future Trends
5.5.1 Rising Trend of Personalized Vaccines
5.6 Impact of Drivers and Restraints:
6. Human Vaccine Adjuvants Market – Global Market Analysis
6.1 Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 – 2030
6.2 Human Vaccine Adjuvants Market Forecast Analysis
7. Human Vaccine Adjuvants Market Analysis – by Type
7.1 Particulate Adjuvant
7.1.1 Overview
7.1.2 Particulate Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.2 Emulsion Adjuvant
7.2.1 Overview
7.2.2 Emulsion Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.3 Combination Adjuvant
7.3.1 Overview
7.3.2 Combination Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Others
7.4.1 Overview
7.4.2 Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8. Human Vaccine Adjuvants Market Analysis – by Application
8.1 Influenza
8.1.1 Overview
8.1.2 Influenza: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.2 Hepatitis
8.2.1 Overview
8.2.2 Hepatitis: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.3 Human papilloma virus (HPV)
8.3.1 Overview
8.3.2 Human papilloma virus (HPV): Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Others
8.4.1 Overview
8.4.2 Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9. Human Vaccine Adjuvants Market Analysis – by End User
9.1 Pharmaceutical and Biotechnology Companies
9.1.1 Overview
9.1.2 Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.2 CMOs and CROs
9.2.1 Overview
9.2.2 CMOs and CROs: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Others
9.3.1 Overview
9.3.2 Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10. Human Vaccine Adjuvants Market – Geographical Analysis
10.1 Overview
10.2 North America
10.2.1 North America Human Vaccine Adjuvants Market Overview
10.2.2 North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.2.3 North America: Human Vaccine Adjuvants Market Breakdown, by Type
10.2.3.1 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.2.4 North America: Human Vaccine Adjuvants Market Breakdown, by Application
10.2.4.1 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.2.5 North America: Human Vaccine Adjuvants Market Breakdown, by End User
10.2.5.1 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.2.6 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.2.6.1 North America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.2.6.2 United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.2.6.2.1 United States: Human Vaccine Adjuvants Market Breakdown, by Type
10.2.6.2.2 United States: Human Vaccine Adjuvants Market Breakdown, by Application
10.2.6.2.3 United States: Human Vaccine Adjuvants Market Breakdown, by End User
10.2.6.3 Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.2.6.3.1 Canada: Human Vaccine Adjuvants Market Breakdown, by Type
10.2.6.3.2 Canada: Human Vaccine Adjuvants Market Breakdown, by Application
10.2.6.3.3 Canada: Human Vaccine Adjuvants Market Breakdown, by End User
10.2.6.4 Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.2.6.4.1 Mexico: Human Vaccine Adjuvants Market Breakdown, by Type
10.2.6.4.2 Mexico: Human Vaccine Adjuvants Market Breakdown, by Application
10.2.6.4.3 Mexico: Human Vaccine Adjuvants Market Breakdown, by End User
10.3 Europe
10.3.1 Europe Human Vaccine Adjuvants Market Overview
10.3.2 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.3 Europe: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.3.1 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.3.4 Europe: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.4.1 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.3.5 Europe: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.5.1 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.3.6 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.3.6.1 Europe: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.3.6.2 Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.2.1 Germany: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.2.2 Germany: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.2.3 Germany: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.3 United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.3.1 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.3.2 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.3.3 United Kingdom: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.4 France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.4.1 France: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.4.2 France: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.4.3 France: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.5 Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.5.1 Italy: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.5.2 Italy: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.5.3 Italy: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.6 Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.6.1 Spain: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.6.2 Spain: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.6.3 Spain: Human Vaccine Adjuvants Market Breakdown, by End User
10.3.6.7 Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.3.6.7.1 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Type
10.3.6.7.2 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by Application
10.3.6.7.3 Rest of Europe: Human Vaccine Adjuvants Market Breakdown, by End User
10.4 Asia Pacific
10.4.1 Asia Pacific Human Vaccine Adjuvants Market Overview
10.4.2 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.3 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.3.1 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.4.4 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.4.1 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.4.5 Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.5.1 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.4.6 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.4.6.1 Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.4.6.2 China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.2.1 China: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.2.2 China: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.2.3 China: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.3 Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.3.1 Japan: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.3.2 Japan: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.3.3 Japan: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.4 India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.4.1 India: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.4.2 India: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.4.3 India: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.5 Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.5.1 Australia: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.5.2 Australia: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.5.3 Australia: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.6 South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.6.1 South Korea: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.6.2 South Korea: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.6.3 South Korea: Human Vaccine Adjuvants Market Breakdown, by End User
10.4.6.7 Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.4.6.7.1 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Type
10.4.6.7.2 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by Application
10.4.6.7.3 Rest of APAC: Human Vaccine Adjuvants Market Breakdown, by End User
10.5 Middle East and Africa
10.5.1 Middle East and Africa Human Vaccine Adjuvants Market Overview
10.5.2 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.3 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.3.1 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.5.4 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.4.1 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.5.5 Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
10.5.5.1 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.5.6 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.5.6.1 Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.5.6.2 Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.6.2.1 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.6.2.2 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.6.2.3 Saudi Arabia: Human Vaccine Adjuvants Market Breakdown, by End User
10.5.6.3 South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.6.3.1 South Africa: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.6.3.2 South Africa: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.6.3.3 South Africa: Human Vaccine Adjuvants Market Breakdown, by End User
10.5.6.4 United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.6.4.1 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.6.4.2 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.6.4.3 United Arab Emirates: Human Vaccine Adjuvants Market Breakdown, by End User
10.5.6.5 Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.5.6.5.1 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type
10.5.6.5.2 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application
10.5.6.5.3 Rest of Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User
10.6 South and Central America
10.6.1 South and Central America Human Vaccine Adjuvants Market Overview
10.6.2 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 | (US$ Million)
10.6.3 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
10.6.3.1 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Type
10.6.4 South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
10.6.4.1 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Application
10.6.5 South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User
10.6.5.1 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by End User
10.6.6 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.6.6.1 South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast Analysis – by Country
10.6.6.2 Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.6.6.2.1 Brazil: Human Vaccine Adjuvants Market Breakdown, by Type
10.6.6.2.2 Brazil: Human Vaccine Adjuvants Market Breakdown, by Application
10.6.6.2.3 Brazil: Human Vaccine Adjuvants Market Breakdown, by End User
10.6.6.3 Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.6.6.3.1 Argentina: Human Vaccine Adjuvants Market Breakdown, by Type
10.6.6.3.2 Argentina: Human Vaccine Adjuvants Market Breakdown, by Application
10.6.6.3.3 Argentina: Human Vaccine Adjuvants Market Breakdown, by End User
10.6.6.4 Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
10.6.6.4.1 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type
10.6.6.4.2 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application
10.6.6.4.3 Rest of South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User
11. Industry Landscape
11.1 Overview
12. Company Profiles
12.1 Novartis AG
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Dynavax Technologies Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 CSL Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Seppic SA
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 SPI Pharma Inc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Hawaii Biotech Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Croda International Plc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Novavax Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Phibro Animal Health Corp
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Creative Biolabs Inc
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. Appendix
13.1 About The Insight Partners
13.2 Glossary of Terms
List of Tables
Table 1. Human Vaccine Adjuvants Market Segmentation
Table 2. Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Table 3. Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Type
Table 4. Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Application
Table 5. Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by End User
Table 6. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 7. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 8. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 9. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 10. United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 11. United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 12. United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 13. Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 14. Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 15. Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 16. Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 17. Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 18. Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 19. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 20. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 21. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 22. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 23. Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 24. Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 25. Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 26. United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 27. United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 28. United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 29. France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 30. France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 31. France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 32. Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 33. Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 34. Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 35. Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 36. Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 37. Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 38. Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 39. Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 40. Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 41. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 42. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 43. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 44. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 45. China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 46. China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 47. China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 48. Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 49. Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 50. Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 51. India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 52. India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 53. India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 54. Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 55. Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 56. Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 57. South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 58. South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 59. South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 60. Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 61. Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 62. Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 63. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 64. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 65. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 66. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 67. Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 68. Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 69. Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 70. South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 71. South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 72. South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 73. United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 74. United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 75. United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 76. Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 77. Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 78. Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 79. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 80. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 81. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 82. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Country
Table 83. Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 84. Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 85. Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 86. Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Type
Table 87. Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 88. Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by End User
Table 89. Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by Type
Table 90. Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million) – by Application
Table 91. Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million) – by End User
Table 92. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 93. Glossary of Terms, Global Human Vaccine Adjuvants Market
List of Figures
Figure 1. Human Vaccine Adjuvants Market Segmentation, by Geography
Figure 2. PEST Analysis
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Human Vaccine Adjuvants Market Breakdown by Geography, 2022 and 2030 (%)
Figure 5. Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 – 2030
Figure 6. Human Vaccine Adjuvants Market Share (%) – by Type (2022 and 2030)
Figure 7. Particulate Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Emulsion Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Combination Adjuvant: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 10. Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Human Vaccine Adjuvants Market Share (%) – by Application (2022 and 2030)
Figure 12. Influenza: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Hepatitis: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Human papilloma virus (HPV): Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Human Vaccine Adjuvants Market Share (%) – by End User (2022 and 2030)
Figure 17. Pharmaceutical and Biotechnology Companies: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. CMOs and CROs: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Others: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Human Vaccine Adjuvants Market Breakdown by Region, 2022 and 2030 (%)
Figure 21. North America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 22. North America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 23. North America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 24. North America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 25. North America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 26. United States: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 27. Canada: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 28. Mexico: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 29. Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 30. Europe: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 31. Europe: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 32. Europe: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 33. Europe: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 34. Germany: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 35. United Kingdom: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 36. France: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 37. Italy: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 38. Spain: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 39. Rest of Europe: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 40. Asia Pacific: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 41. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 42. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 43. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 44. Asia Pacific: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 45. China: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 46. Japan: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 47. India: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 48. Australia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 49. South Korea: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 50. Rest of APAC: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 51. Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 52. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 53. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 54. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 55. Middle East and Africa: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 56. Saudi Arabia: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 57. South Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 58. United Arab Emirates: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 59. Rest of Middle East and Africa: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 60. South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 61. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Type (2022 and 2030)
Figure 62. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Application (2022 and 2030)
Figure 63. South and Central America: Human Vaccine Adjuvants Market Breakdown, by End User (2022 and 2030)
Figure 64. South and Central America: Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 65. Brazil: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 66. Argentina: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
Figure 67. Rest of South and Central America: Human Vaccine Adjuvants Market – Revenue and Forecast to 2030(US$ Million)
The List of Companies - Human Vaccine Adjuvants Market
- Novartis AG
- Dynavax Technologies Corp
- CSL Ltd
- Seppic SA
- SPI Pharma Inc
- Hawaii Biotech Inc
- Croda International Plc
- Novavax Inc
- Phibro Animal Health Corp
- Creative Biolabs Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Trends and growth analysis reports related to Human Vaccine Adjuvants Market
Jan 2024
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2024
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2024
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2024
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2024
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2024
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jan 2024
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jan 2024
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)